SUMMARY
The management of relapsing gynaecologic cancers depends on whether the relapse is oligometastatic (OMD) or polymetastatic (PMD). Stereotactic body radiotherapy (SBRT) is rapidly emerging as an additional treatment option for OMD, defined as a limited and treatable amount of metastases, due to its ability to deliver high radiation doses to small tumour volumes in a short time frame.1–5 SBRT is minimally invasive, cost-effective, and offers high local control rates with minimal toxicity. It has shown activity in chemo-resistant disease and may also act as an immune response activator or synergise with PARP inhibitors (PARPi).
(BELG J MED ONCOL 2025;19(4):190–193)
